244
Participants
Start Date
January 31, 2007
Primary Completion Date
April 30, 2014
Study Completion Date
April 30, 2014
alpha-lipoic acid
Oral two 300 mg ALA sustained release tablets initiated 4 days after last dose of platinum and discontinued 2 days before next scheduled platinum dose, continued for 24 weeks.
placebo
Given orally two similar color and sized placebo control tablets three times a day continued for 24 weeks.
CCOP - Main Line Health, Wynnewood
CCOP - Greenville, Greenville
Horizon Oncology Center, Lafayette
Marshfield Clinic - Marshfield Center, Marshfield
CCOP - Metro-Minnesota, Saint Louis Park
Cancer Research for the Ozarks, Springfield
Cabrini Center for Cancer Care at Christus St. Frances Cabrini Hospital, Alexandria
Hembree Mercy Cancer Center at St. Edward Mercy Medical Center, Fort Smith
CCOP - Scott and White Hospital, Temple
CCOP - Columbia River Oncology Program, Portland
CCOP - Wichita, Wichita
CCOP - Kalamazoo, Kalamazoo
University of Texas M.D. Anderson CCOP Research Base, Houston
National Cancer Institute (NCI)
NIH
M.D. Anderson Cancer Center
OTHER